Roth Capital Upgrades Salix Pharmaceuticals (SLXP) to Buy
More News related to SLXP
- Salix Pharmaceuticals Reports 3Q2009 Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Salix Pharmaceuticals to Host Analyst Day on November 18
- Salix Pharmaceuticals to Present at Credit Suisse Conference
- Salix Pharma (SLXP) Announces the Issuance of Two Patents Related to Rifaximin
More News related to Upgrades
- XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
- Natixis Bleichroeder Downgrades Tenaris S.A. (TS) to Reduce
- Bank of America Downgrades Seneca Foods (SENEB) from Buy
- RBC Downgrades Intrepid Potash (IPI) to Sector Perform
Roth Capital upgrades Salix Pharmaceuticals (Nasdaq: SLXP) from Hold to Buy. Price target $12.50.
To see more analyst ratings on SLXP Click Here.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract.
Related Categories
UpgradesStocks Mentioned
+0.20Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
